Castillejo Adela, Vargas Gardenia, Castillejo María Isabel, Navarro Matilde, Barberá Víctor Manuel, González Sara, Hernández-Illán Eva, Brunet Joan, Ramón y Cajal Teresa, Balmaña Judith, Oltra Silvestre, Iglesias Sílvia, Velasco Angela, Solanes Ares, Campos Olga, Sánchez Heras Ana Beatriz, Gallego Javier, Carrasco Estela, González Juan Dolors, Segura Angel, Chirivella Isabel, Juan María José, Tena Isabel, Lázaro Conxi, Blanco Ignacio, Pineda Marta, Capellá Gabriel, Soto José Luis
Molecular Genetics Laboratory, Elche University Hospital, Elche, Alicante, Spain.
Hereditary Cancer Program, Catalan Institute of Oncology, ICO-IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
Eur J Cancer. 2014 Sep;50(13):2241-50. doi: 10.1016/j.ejca.2014.05.022. Epub 2014 Jun 18.
Individuals with tumours showing mismatch repair (MMR) deficiency not linked to germline mutations or somatic methylation of MMR genes have been recently referred as having 'Lynch-like syndrome' (LLS). The genetic basis of these LLS cases is unknown. MUTYH-associated polyposis patients show some phenotypic similarities to Lynch syndrome patients. The aim of this study was to investigate the prevalence of germline MUTYH mutations in a large series of LLS patients.
Two hundred and twenty-five probands fulfilling LLS criteria were included in this study. Screening of MUTYH recurrent mutations, whole coding sequencing and a large rearrangement analysis were undertaken. Age, sex, clinical, pathological and molecular characteristics of tumours including KRAS mutations were assessed.
We found a prevalence of 3.1% of MAP syndrome in the whole series of LLS (7/225) and 3.9% when only cases fulfilling clinical criteria were considered (7/178). Patients with MUTYH biallelic mutations had more adenomas than monoallelic (P=0.02) and wildtype patients (P<0.0001). Six out of nine analysed tumours from six biallelic MUTYH carriers harboured KRAS-p.G12C mutation. This mutation was found to be associated with biallelic MUTYH germline mutation when compared with reported series of unselected colorectal cancer cohorts (P<0.0001).
A proportion of unexplained LLS cases is caused by biallelic MUTYH mutations. The obtained results further justify the inclusion of MUTYH in the diagnostic strategy for Lynch syndrome-suspected patients.
肿瘤显示错配修复(MMR)缺陷但与MMR基因的种系突变或体细胞甲基化无关的个体最近被称为患有“林奇样综合征”(LLS)。这些LLS病例的遗传基础尚不清楚。MUTYH相关息肉病患者表现出与林奇综合征患者的一些表型相似性。本研究的目的是调查一大系列LLS患者中种系MUTYH突变的患病率。
本研究纳入了225名符合LLS标准的先证者。进行了MUTYH复发性突变筛查、全编码测序和大片段重排分析。评估了肿瘤的年龄、性别、临床、病理和分子特征,包括KRAS突变。
在整个LLS系列中,我们发现MAP综合征的患病率为3.1%(7/225),仅考虑符合临床标准的病例时患病率为3.9%(7/178)。MUTYH双等位基因突变的患者比单等位基因患者(P=0.02)和野生型患者(P<0.0001)有更多的腺瘤。来自6名双等位基因MUTYH携带者的9个分析肿瘤中有6个携带KRAS-p.G12C突变。与报道的未选择的结直肠癌队列系列相比,发现该突变与双等位基因MUTYH种系突变相关(P<0.0001)。
一部分原因不明的LLS病例是由双等位基因MUTYH突变引起的。所得结果进一步证明将MUTYH纳入疑似林奇综合征患者的诊断策略是合理的。